Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabiralizumab in PVNS/dt-TGCT
NCT02471716Phase 2Completed
- Sponsor
- Five Prime Therapeutics, Inc.
- Start
- Jun 2015
- Primary completion
- Apr 2020
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of cabiralizumab in tenosynovial giant cell tumor (TGCT), sponsored by Five Prime Therapeutics, Inc.. Started Jun 2015; status: completed.
02
Drugs
cabiralizumab
03
Conditions
tenosynovial giant cell tumor (TGCT)
Beyond the preview
Go deeper on NCT02471716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02471716.